Expert Interviews

The assistant professor of Urology at The University of Texas MD Anderson Cancer Center spoke about the results of a study which evaluated the use of the Mediterranean diet in men with localized prostate cancer on active surveillance.

In this trial, investigators launched RxPONDER, in which 5015 patients with a recurrence score between 0 and 25 were randomized to endocrine therapy alone or chemotherapy followed by endocrine therapy.

The phase 1b/2 trial evaluated a single, low-dose infusion of ciltacabtagene autoleucel (cilta-cel; JNJ-68284528) in heavily pretreated patients with relapsed or refractory multiple myeloma.

A leading expert in the field of esophageal cancers discussed his upcoming research on cabozantinib combined with pembrolizumab to treat gastroesophageal adenocarcinoma at the 2021 ASCO Gastrointestinal Cancers Symposium.

The hospitalist at Memorial Sloan Kettering Cancer Center spoke about the design of a study which evaluated the use of 177Lu-DOTATATE in patients with well-differentiated, high-grade neuroendocrine tumors.

The expert in hematology/oncology spoke about the study which evaluated the use of peptide receptor radionuclide therapy in patients with well-differentiated neuroendocrine tumors.

SWOG S1406 evaluated the use of irinotecan and cetuximab (Erbitux) with or without vemurafenib (Zelboraf) in patients with BRAF V600E-mutated metastatic colorectal cancer who had been previously treated with 1 or 2 regimens.

Based on findings from the trial of ciltacabtagene autoleucel, further investigation of the therapy in other populations of patients with multiple myeloma is already underway.

IDH1/2 mutations have been detected in nearly 20% of patients with acute myeloid leukemia.

Merryman provided background for the study design investigating patients with relapsed or refractory diffuse large B-cell lymphoma.

A recent study sought to evaluate the 21-gene Oncotype Dx Recurrence Score in nonmetastatic HR-positive, HER2-negative breast cancer.

The goal of the CARTITUDE-1 study was to evaluate the use of ciltacabtagene autoleucel (cilta-cel; JNJ-68284528) chimeric antigen receptor T-cell therapy in heavily pretreated patients with relapsed or refractory multiple myeloma.

An industry leader in psychosocial oncology detailed the importance of patient-reported outcomes to the field as a whole and emphasized a number of key details to remember when examining these end points.

Hypogammaglobulinemia was found to be nearly universal for patients with multiple myeloma during treatment with daratumumab, suggesting a role for intravenous immunoglobulin.

The study was designed to evaluate the use of ciltacabtagene autoleucel in patients with relapsed or refractory multiple myeloma in the United States.

The interview features comments on the emergence of T-cell engagers for therapy in patients with multiple myeloma made during the 2020 ASH Meeting & Exposition.

A study of the use of intravenous immunoglobulin on infections in patients with multiple myeloma receiving daratumumab suggested a role for the strategy in this patient population.